A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
NCT05844228
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Impairment
Interventions
DRUG:
VIR-2218
Sponsor
Vir Biotechnology, Inc.